Crinetics Pharmaceuticals, Inc.

For the period ended Jun 30, 2026. Filed Aug 3, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2026 · Filed Aug 3, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Operations and Comprehensive Loss

Checking your notes…

(in thousands, except per share data)

	Three months ended June 30,		Six months ended June 30,
	2026	2025	2026	2025
Revenue:
Product revenue, net	$24,038	$—	$34,344	$—
Collaboration and license revenue	1,080	1,031	1,508	1,392
Total revenue	25,118	1,031	35,852	1,392
Operating expenses:
Cost of product revenue	154	—	354	—
Research and development	99,850	80,301	199,931	156,541
Selling, general and administrative	57,573	49,842	108,404	85,368
Total operating expenses	157,577	130,143	308,689	241,909
Loss from operations	(132,459)	(129,112)	(272,837)	(240,517)
Other income (expense):
Interest income	12,027	13,455	24,691	28,289
Other (expense) income, net	(423)	20	(554)	(183)
Total other income, net	11,604	13,475	24,137	28,106
Net loss	(120,855)	(115,637)	(248,700)	(212,411)
Net loss per share:
Net loss per share — basic and diluted	$(1.14)	$(1.23)	$(2.37)	$(2.27)
Weighted average shares — basic and diluted	105,560	93,791	104,834	93,448
Other comprehensive income (loss):
Unrealized gain (loss) on investment securities	$(1,899)	$(347)	$(5,046)	$686
Unrealized gain (loss) on foreign currency	145	(34)	173	(28)
Total other comprehensive income (loss)	(1,754)	(381)	(4,873)	658
Comprehensive loss	$(122,609)	$(116,018)	$(253,573)	$(211,753)

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.